林国文 Prof. Guowen Lin

泌尿外科副主任医师 / 医学博士 / 硕士生导师

专家风采 Expert Highlights

泌尿系统良恶性肿瘤诊治 Diagnosis and treatment of benign and malignant urologic tumors 前列腺癌精准诊疗与根治手术 Precision prostate cancer diagnosis and radical surgery 年主刀根治手术超400台 / 穿刺术超600台 400+ radical surgeries and 600+ targeted biopsies annually
重点方向 Primary Focus
前列腺癌根治术、精准融合穿刺、局部晚期与转移性前列腺癌综合治疗 Radical prostatectomy, fusion-targeted biopsy, and integrated treatment for locally advanced and metastatic prostate cancer.
临床特色 Clinical Strengths
机器人/荧光导航手术、神经保留与盆腔结构最大化保留、冷冻与不可逆电穿孔消融 Robot and fluorescence-guided surgery, nerve-sparing pelvic-preservation techniques, and cryo/IRE ablation.
科研与学术 Research and Academia
主持国家自然科学基金等多项课题,发表30余篇论文 PI of NSFC and multiple major grants, with 30+ peer-reviewed publications.
林国文医生照片 / Prof. Guowen Lin portrait

林国文 教授

泌尿外科副主任医师、医学博士、硕士生导师。

医学专长:泌尿系统各种良恶性肿瘤的诊治。擅长:前列腺癌根治手术(机器人、荧光系统导航)、保留性神经和最大程度保留盆腔结构的前列腺癌根治术、前列腺精准穿刺术(融合靶向穿刺)、局部晚期前列腺癌扩大根治术、转移性前列腺癌系统用药和手术治疗、前列腺冷冻/不可逆电穿孔消融术。每年主刀根治手术超400台,精准穿刺术超600台。

学术任职

  • 中国抗癌协会泌尿男生殖系肿瘤专业委员会委员
  • 中国初级卫生保健基金会泌尿肿瘤精准诊疗管理委员会常委
  • 中国生物工程学会肿瘤药物基因组学专业委员会委员
  • 中国中西医结合学会基层工作委员会委员
  • 中国医药教育协会医疗装备委员会委员
  • 上海市抗癌协会癌症康复与姑息治疗专委会青年常委
  • 上海市抗癌协会癌症预防与筛查专业委员会委员
  • 上海市抗癌协会肿瘤药物临床研究专业委员会委员
  • 《前列腺穿刺中国专家共识》、《局部高危前列腺癌围术期治疗共识》主笔专家
  • 《中国癌症杂志》、《Scientific Reports》编委
  • CDFI超声师、高级健康管理师

科研情况:作为课题负责人主持国家自然科学基金,上海市自然科学基金,上海医学创新研究基金,上海市卫健委基金、CSCO临床肿瘤研究基金等课题。国内外权威学术刊物发表30余篇学术论文。在前列腺癌根治手术解剖、前列腺穿刺图像融合、晚期患者药物治疗方面做出积极探索。

Prof. Guowen Lin

Associate Chief Physician in Urology, MD, and Master's Supervisor.

Medical Specialty: Diagnosis and treatment of a wide range of benign and malignant urologic tumors. Expertise includes radical prostatectomy (robot-assisted and fluorescence-guided), nerve-sparing and maximal pelvic-structure-preserving radical prostatectomy, precision prostate biopsy (fusion-targeted biopsy), extended radical surgery for locally advanced prostate cancer, systemic and surgical treatment for metastatic prostate cancer, and prostate cryoablation/irreversible electroporation (IRE). He performs over 400 radical surgeries and over 600 precision biopsies per year.

Academic Appointments:

  • Member, Urogenital Tumor Committee, Chinese Anti-Cancer Association.
  • Standing Committee Member, Precision Urologic Oncology Diagnosis and Treatment Management Committee, China Primary Health Care Foundation.
  • Member, Tumor Pharmacogenomics Committee, Chinese Society of Biotechnology.
  • Member, Primary Care Committee, Chinese Association of Integrative Medicine.
  • Member, Medical Equipment Committee, China Medical Education Association.
  • Youth Standing Committee Member, Cancer Rehabilitation and Palliative Care Committee, Shanghai Anti-Cancer Association.
  • Member, Cancer Prevention and Screening Committee, Shanghai Anti-Cancer Association.
  • Member, Clinical Tumor Drug Research Committee, Shanghai Anti-Cancer Association.
  • Lead drafting expert for Chinese expert consensus on prostate biopsy and perioperative treatment of locally high-risk prostate cancer.
  • Editorial board member of China Oncology and Scientific Reports.
  • CDFI ultrasonographer and senior health manager.

Research: As principal investigator, he has led projects funded by the National Natural Science Foundation of China, Shanghai Natural Science Foundation, Shanghai Medical Innovation Research Fund, Shanghai Municipal Health Commission Fund, and CSCO Clinical Oncology Research Fund. He has published over 30 papers in leading domestic and international journals, with active contributions in radical prostatectomy anatomy, image-fusion prostate biopsy, and drug treatment strategies for advanced patients.

医学免责声明

本网站仅提供医院与医生团队介绍、医疗资源信息展示、患者故事、医院新闻和国际患者服务流程说明。本网站不提供医学诊断、治疗建议、处方、急救服务或在线问诊。任何医学决策均应由持牌医生和医疗机构在正式评估后作出。如遇紧急医疗情况,请立即联系当地急救服务。

联系我们